research use only

Cephalexin Bacterial chemical

Name: Cephalexin
Brand: Selleck Chemicals
SKU: S1502
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S1502

Cephalexin (Cefalexin) is an antibiotic that can treat a number of bacterial infections.

Chemical Structure

Molecular Weight: 347.39

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.79%

99.79

Related Targets	Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease SARS-CoV HIV Protease Influenza Virus β-lactamase Integrase HBV CMV Neuraminidase HCV HSV RSV Enterovirus Thioredoxin Reductase 3C-Like Protease Ribosomal Peptidyl Transferase HPV
Related Products	Berberine BTZ043 Racemate Teicoplanin Ornidazole Skatole Berberine Sulfate Pipemidic acid Ceftiofur PBTZ169 Aminothiazole Furagin Furaltadone HCl Nimorazole Trigonelline Hydrochloride Methyl α-D-mannopyranoside Artemisic acid Pefloxacin Mesylate Protionamide 6-Methoxydihydrosanguinarine

Chemical Information, Storage & Stability

Molecular Weight	347.39	Formula	C₁₆H₁₇N₃O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	15686-71-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Cefalexin			Smiles	CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O

Solubility

In vitro
Batch:

Water : 10 mg/mL

DMSO : 5 mg/mL ( (14.39 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Cephalexin uptake by human MATE1-expressing human embryonic kidney 293 cells exhibits saturable kinetics with K(m) = 5.9 mM and a bell-shaped pH profile with a maximum at pH 7.0. ^[1] This compound results in overestimation of glucose concentration, but only in the samples that contain the highest antimicrobial concentration (2,400microg/mL) and only for the tablet. ^[2] It increases the activity of superficial mucous cells and orifice mucous cells of gastric glands, and inhibits the activity of cervix mucous cells. ^[3]
In vivo	Cephalexin causes a slight prolongation of 1-stage prothrombin time (PT) and activated partial thromboplastin time (PTT) and slight decrease in fibrinogen concentration in healthy dogs. This compound causes a significant increase in 1-stage PT and activated PTT, amoxicillin causes a significant increase in activated PTT, and enrofloxacin causes a significant decrease in fibrinogen concentration. ^[4] This chemical results in high numbers of E. coli producing plasmid-mediated CMY-2 β-lactamase at the end of the treatment period in dogs. ^[5]
References	https://pubmed.ncbi.nlm.nih.gov/20484555/ https://pubmed.ncbi.nlm.nih.gov/15124885/ https://pubmed.ncbi.nlm.nih.gov/16145970/ https://pubmed.ncbi.nlm.nih.gov/16579747/ https://pubmed.ncbi.nlm.nih.gov/21497459/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04916951	Enrolling by invitation	Neonatal Infection	University of Colorado Denver	July 14 2021	Phase 1
NCT03802552	Completed	Osteomyelitis\|Septic Arthritis\|Pyomyositis	University of Colorado Denver	May 1 2019	Phase 1
NCT02490670	Completed	Healthy	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica S.A. de C.V.	July 2015	Phase 1
NCT02123459	Completed	Healthy Volunteers	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica S.A. de C.V.	May 2014	Phase 1
NCT02123472	Completed	Healthy Volunteers	Eli Lilly and Company\|Investigacion Farmacologica y Biofarmaceutica S.A. de C.V.	May 2014	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):